Abstract
In 2021, there were 8.4 million cases of type 1 diabetes mellitus (T1DM) worldwide which projected to reach 17.4 million cases in 2040. Patients diagnosed with T1DM are on life-long insulin injections in order to regulate their blood glucose levels. The standard insulin therapy and subsequent monitoring HbA1c is no longer sufficient for T1DM patients management. Instead, postprandial hyperglycemia as well as glycemic variations should be minimized to reach near normoglycemic state. To do so, intensive insulin therapy should be introduced so as to restore homeostatic glycemic control.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
